and therefore the specific contributory roles of enzymatic versus non-enzymatic of ox-LDL generation remains to be determined. Although it is reported that oxidation of LDL by 15-LOX can be processed via direct reaction with phospholipids, 9, 10) 15-LOX directly oxygenates both polyunsaturated fatty acids (PUFAs) and cholesteryl esters formed between the carboxyl group (-COOH) of PUFAs and the hydroxyl group (-OH) of cholesterol (see Fig. 1A ). 2, 11, 12) Among the cholesteryl esters in LDL, cholesteryl linoleate is the most abundant substrate for fatty acid oxidation and represents the major oxidizable lipid. 9, 11, 13) Further, LOX enzymes can generate the formation of conjugated dienes and lipid hydroperoxides that may be obligatory intermediates in LDL oxidative modification. 9, 14) To more clearly dissect the contributing roles of 15-LOX versus non-enzymatic pathways in LDL oxidation, in this study we utilized a highly potent and selective inhibitor of 15-LOX-catalyzed linoleic acid oxygenation, cannabidiol-2Ј,6Ј-dimethyl ether (CBDD), recently identified by our laboratory. 15) CBDD exhibits an IC 50 potency of 0.28 mM and selectivity indicated by a 5-LOX/15-LOX ratio 
MATERIALS AND METHODS

Reagents D
9 -Tetrahydrocannabinol (D 9 -THC) was isolated and purified from the cannabis leaves according to the methods described elsewhere. 15, 16) CBD and CBDD were purchased from Tocris Bioscience (Ellisville, MO, U.S.A.) and Cayman Chemical Co. (Ann Arbor, MI, U.S.A.), respectively. Purity of D 9 -THC was Ͼ95%, as assessed by gas chromatography. 15, 16) Arachidonic acid, linoleic acid, and nordihydroguaiaretic acid (NDGA) was purchased from Cayman Chemical Co. Human plasma LDL (purity Ͼ95%) (lot nos. D00067046 and D00096308) was purchased from Calbiochem (La Jolla, CA, U.S.A.). Cholesteryl linoleate was purchased from Sigma-Aldrich Corp. (St. Louis, MO, U.S.A.). All other reagents were of analytical grade.
Enzyme Sources Measurements of the 5-LOX and 15-LOX activities were conducted using a commercially available LOX inhibitor screening assay kit (Cayman Chemical Co.). 5-LOX (lot No. 0400028-1) and 15-LOX (lot No. 0406588-4) enzymes were purchased from Cayman Chemical Co. All inhibitors added to the reaction system were prepared immediately prior to use. Following the enzymatic reactions, the resulting hydroperoxides were treated with chromogen to develop the reaction and then absorbance intensities were determined spectrophotometrically at 490 nm with a Molecular Devices E max Precision Microplate Reader (Molecular Devices, Inc., Philadelphia, PA, U.S.A.). No colorimetric change was observed in control incubations performed in the absence of enzymes or with heat-denatured enzymes when added with chemical inhibitors and chromogen. The concentration ranges of compounds used in this study were determined empirically based on their solubilities and levels demonstrated not to interfere with chromogen detection. Each assay was performed in triplicate.
Assay for Formation of Conjugated Dienes 15-LOX and PUFAs (arachidonic acid or linoleic acid) or cholesteryl linoleate were incubated in the presence or absence of CBDD or CBD for various times in spectrophotometric cuvettes (1.0 cm light path). Incubations were performed in 100 mM borate buffer, pH 9.0 at room temperature. 17, 18) Absorbance at 234 nm was periodically recorded after addition of 15-LOX. Results are expressed as an increase in absorbance from the zero time reaction mixture.
Ox-LDL Preparation and Agarose Gel Electrophoresis
Immediately prior to the experiments, extensive dialysis was performed to remove ethylenediaminetetraacetic acid (EDTA) added during the isolation of human LDL. After dialysis, LDL was used either immediately or subsequent to storage for Ͻ48 h at 4°C in the dark and under argon. Protein contents were determined by the Bradford protein assay reagent (Bio-Rad Laboratories Inc., Richmond, CA, U.S.A.) or Precision Red Advanced Protein Assay Reagent #2 (Cytoskeleton Inc., Denver, CO, U.S.A.). Oxidation of LDL into ox-LDL, mediated by copper (Cu 2ϩ , CuSO 4 )-induced non-enzymatic oxidation or 15-LOX-induced enzymatic oxidation, was determined at 37°C for 5 h, in the presence or absence of CBDD. Subsequent to separation by agarose gel electrophoresis, LDL was stained with Coomassie Brilliant Blue (CBB) G250 (Bio-Safe TM Coomassie Stain, Bio-Rad Laboratories Inc.). No observable formation of ox-LDL was detected for 2 h incubation. Further details of the experiments are described in the legend to Fig. 5 and the cited literature. , resulting ox-LDLs were separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (4% acrylamide gel), and then Western blot analysis was performed according to the methods previously. 19) An antibody to human apolipoprotein B (predicted molecular weight of 516 kDa) was used (Abcam, Cambridge, MA, U.S.A.).
Data Analysis The IC 50 value was determined from the curves plotting enzymatic activity versus inhibitor concentrations. The details of the calculations were described previously. 15, 16, 20) All statistical analyses were performed by Scheffé's F test, a post-hoc test for analyzing results of analysis of variance (ANOVA) data. The calculations were performed using Statview5.0J software (SAS Institute Inc., Cary, NC, U.S.A.). Differences were considered significant at p values Ͻ0.05.
RESULTS AND DISCUSSION
CBDD Inhibits 15-LOX-Catalyzed PUFAs Oxygenation
Since LOX activity is conventionally measured with PUFA substrates, 14, 18) we initially tested the inhibitory effects of CBDD (Fig. 1B) , as well as several structurally related compounds including NDGA, a well-characterized pan-LOX inhibitor, on 15-LOX-catalyzed oxygenation of arachidonic acid (AA), by measuring the formation of hydroperoxides. The compounds tested in our investigation have previously been established as inhibitors of 15-LOX-calayzed linoleic acid (LA) oxygenation. 15, 16) With the exception of CBDD, the other compounds contain reducing moieties, such as catechol, resorcinol, and phenol in their respective structures. 15, 16) LOX enzymes require the ferric state (Fe 3ϩ ) to initiate their enzymatic reaction. 17) As expected, 5 mM NDGA significantly inhibited 15-LOX activity. Although a resorcinol ring-containing CBD potently inhibited 15-LOX-catalyzed LA oxygenation (IC 50 ϭ2.56 mM), possibly via direct inhibition and reduction of Fe 3ϩ into Fe 2ϩ (ferrous state) in the active center of 15-LOX, 17) the enzymatic reaction of AA was only poorly inhibited by this agent at 5 mM. At 50 mM, CBD, CBDD, and D
9
-THC all significantly inhibited the activity of the enzyme (Fig. 2A) . Although at 5 mM both CBDD and D
-THC exhibited strong inhibitory effects on 15-LOX, CBDD, whose resorcinolic OH groups are dimethylated, exhibited more potent efficacy than CBD, a prototype of the dimethylated form ( Fig. 2A) . The IC 50 vales for the inhibition of 15-LOX by CBDD and CBD were determined as 0.92 mM (Fig. 2B ) and 12.38 mM, respectively, suggesting that CBDD inhibits the formation of AA hydroperoxides catalyzed by 15-LOX in addition to LA. Further, 5-LOX-mediated oxygenation of AA was not inhibited by CBDD, even at 50 mM concentrations (data not shown). We also used an alternative methodology to assess the inhibitory effect of CBDD on PUFAs, measuring the effect of CBDD on the formation of conjugated dienes on LA or AA during the oxygenation by 15-LOX, as compared with CBD. In these assays, 15-LOX preferably catalyzed the formation of conjugated dienes of LA over that of AA (Fig.  3A) . The differences in the measured CBDD-mediated IC 50 values between LA (0.28 mM) and AA (0.92 mM) (Fig. 2B ) could perhaps be due to differences in the substrate specificity of 15-LOX that involve LA versus AA interactions or alignment within the active site(s) of the enzyme. In these respects, it has also been suggested that 15-LOX enzymes possess allosteric binding site(s) in the structure, 14, 21) hence allosterism may also account for the differences noted.
Interestingly, as demonstrated in Fig. 3B , the inhibition potential by 1 mM CBDD and CBD on 15-LOX-catalyzed oxygenation of LA (panel a) and AA (panel b), was closely comparable. In general, LOX-catalyzed oxygenation of PUFAs consists of four consecutive reactions: i) hydrogen abstraction, ii) radical rearrangement (conjugated dienes), iii) oxygen insertion (lipid peroxy radicals), and iv) peroxy radical reduction (hydroperoxides).
14) The peroxyl radical formed in step iii) is known to be highly reactive and is capable of propagating the chain reaction. 14) Given the data that CBDD more potently inhibits 15-LOX-catalyzed hydroperoxide formation of PUFAs as compared to CBD (CBDD: IC 50 ϭ0.28 mM for LA; IC 50 ϭ0.92 mM for AA; CBD: IC 50 ϭ2.56 mM for LA; IC 50 ϭ12.38 mM for AA), it is therefore suggested that CBDD more specifically and/or more potently inhibits the reaction step iii) and/or iv) compared with CBD. Further, it appears reasonable to suggest that the CBD-mediated inhibition of 15-LOX might be modified by methylation of the resorcinolic OH groups, leading to gains in CBDD inhibitory selectivity to reaction steps iii) and/or iv). Further studies are required to clarify these exact mechanisms.
Taken together, the results obtained in this investigation firmly demonstrate that CBDD is a potent inhibitor of 15-LOX-catalyzed PUFAs oxygenation, likely via its inhibition of PUFA hydroperoxide formation.
CBDD Interferes with 15-LOX-Mediated CL Oxidation
Since it is reported that 15-LOX effectively targets cholesteryl linoleate (CL) as a substrate, 9, 11, 13) and that the CL is the most abundant substrate for oxidation within the LDL, 19, 13) we focused on our subsequent studies to assess the effects of 10 mM CBDD and CBD on 15-LOX-mediated oxygenation of CL. At "1 mM" concentrations of the cannabinoids, no remarkable inhibitory effects of CBDD and CBD on the reaction were observed (data not shown) (see also the results described in Fig. 5A, lanes 10-12) . It was evident that CBDD was a much more potent inhibitor of the reaction than CBD (Fig. 4) . However, the inhibition profile between CBDD and CBD differed in that CBD effectively squelched the early oxidation phase of the reaction, for approximately 90 s, whereas CBDD addition resulted in a sustained and marked inhibition of the reaction. These data demonstrate that CBDD effectively abrogates 15-LOX-catalyzed CL oxygenation.
We noted that CBDD was a more efficacious inhibitor than 15) The former IC 50 value was determined by varying AA concentrations from 0.1 to 5 mM. CBD when CL (-COO-cholesterol) was used as a substrate, but not LA (-COOH). To better understand the potential mechanistic basis for this difference, we first recognized that esters are much more lipophilic than their respective carboxylic acids. In this respect, we performed an in silico docking simulation study examining CBDD:15-LOX versus CBD:15-LOX interactions. Interestingly, the analysis suggested that the much greater lipophilicity of CBDD was likely an important determinant inhibitory efficacy for 15-LOX, resulting from stronger hydrophobic interactions with amino acid residues within the 15-LOX binding pocket (Takeda and Fukunishi et al., unpublished observations) .
CBDD Interferes with 15-LOX-Mediated ox-LDL Formation It is known that LDL can be oxidized enzymatically or non-enzymatically. 1, 8, 12) The later reaction is mediated by Cu 2ϩ -catalyzed oxidation. 8) A major goal of this study was to assess whether CBDD can inhibit 15-LOXdependent production of ox-LDL formation, since PUFAs, especially LA, are composed as cholesteryl esters in the LDL (see Fig. 1A ). It is established that oxidative modification of LDL results in a greater electrophoretic mobility on agarose gels, since the net negative charge on LDL is increased when oxidized into ox-LDL. 8, 22) Based on this phenomenon, we first studied the effect of CBDD on Cu 2ϩ -mediated ox-LDL formation. Ox-LDL formation was stimulated by 2 mM Cu 2ϩ , while 10 mM CBDD failed to exert any detectable effect on ox-LDL formation (Fig. 5A, lanes 3 vs. 5 ). The absence of CBDD's effect on this pathway was similarly observed even at 100 mM concentrations of CBDD (data not shown), as in the 10 mM CBDD-treated samples shown in Fig. 5A (lane 4) . We next investigated the effect of CBDD on 15-LOX-mediated ox-LDL formation. 15-LOX also catalyzed formation of ox-LDL (Fig. 5A, lane 9) , at a level closely comparable to that of Cu 2ϩ -mediated ox-LDL formation (Fig. 5A, lanes 9 vs. 13). When compared to the results seen for Cu 2ϩ /CBDD (Fig. 5A, lanes 3 vs. 5), CBDD specifically inhibited 15-LOX-mediated ox-LDL formations in a concentrationdependent manner (Fig. 5A , lanes 10-12; 1, 10, and 100 mM, respectively), although 1 mM CBDD could not abrogate the formation of ox-LDL (Fig. 5A, lane 10) . Taken together with the results demonstrated in Fig. 4 , it is suggested that concentration requirements for the CBDD-mediated interference on 15-LOX-catalyzed oxygenation of CL or LDL may be dependent upon the substrates of 15-LOX. It should be noted that CBDD additions themselves did not cause any changes in LDL migration (Fig. 5A, lanes 4, 6-8) .
Further, using after the treatments with 15-LOX or Cu 2ϩ , the intactness of apolipoprotein B (apoB), the most abundant protein in LDL (see Fig. 1A ), was studied by Western blot analysis. ApoB protein can undergo striking degradation, 23) especially by free radical generated in Cu 2ϩ -mediated oxidation reactions. 8) As demonstrated in Fig. 5B(a) , the apoB protein band completely disappeared in the presence of Cu 23) Given that the CBDD-mediated inhibition of ox-LDL formation is attributed to inhibition of the 15-LOX enzyme, the degradation of apoB by Cu 2ϩ should not be effected by CBDD. In support of this idea, no protection was provided by CBDD additions (Fig. 5B(b), lanes 10 vs. 11) . Further, no observable effects of 1-100 mM CBDD alone or in combination with the 15-LOX enzyme were detected (Fig. 5B(b) , lanes 3-5 and 7-9, respectively). As is apparent in Fig. 5A , intensities of the stained CBB band varied from lane 1 to lane 13. We suggest that the variable staining intensities likely reflect protein components in the LDL/ox-LDL, as the LDL and ox-LDL were also stained, with similar migration patterns, by Oil Red O dye which stains lipids in the lipoproteins (data not shown). Taken together, these data strongly suggest that CBDD selectively interferes with enzymatic formation of ox-LDL as catalyzed by 15-LOX, but not with the non-enzymatic formation of ox-LDL from Cu 2ϩ -mediated oxidation. In general, cannabinoids evoke their pharmacological ac- tions via engagement with cannabinoid receptors (CB1 or CB2). 24, 25) Especially, agonists for the CB1 receptor are known to possess psychoactive properties, which can be considered adverse effects. 24, 25) If CBDD behaves as an agonist for CB1 receptor, these actions might limit the clinical utility of the compound. However, CBD is established as a non-psychoactive cannabinoid and exhibits little binding affinity for CB receptors, [24] [25] [26] and similarly, it has been shown that CBDD has no binding affinity for the receptor. 26) Further, although CBD can be converted into a cannabielsoin when incubated with guinea pig liver microsomes that contain dugmetabolizing enzymes including P450s, 19, 20, [27] [28] [29] [30] CBDD is resistant to the liver microsome-mediated metabolism. 27) Therefore, it appears that CBDD offers a potentially positive safety profile, and that CBDD-mediated inhibition of 15-LOX may be retained in in vivo situations.
In sum, these findings suggest that CBDD may be a useful adjuvant in the treatment of atherosclerosis as well as an experimental tool for analyzing the mechanistic details of PUFAs oxygenation by 15-LOX. Further studies will be required to assess the potential in vivo effects of CBDD.
